Angiotensin (1-7): Mechanistic Insights and Experimental Benchmarks

Executive Summary: Angiotensin (1-7) (Ang-(1-7)) is an endogenous heptapeptide derived from angiotensin I or II via peptidase action, acting primarily through the Mas receptor to counter-regulate angiotensin II effects (Oliveira et al., 2025). This peptide modulates key signaling pathways, including PI3K/AKT and ERK, resulting in anti-fibrotic, anti-inflammatory, and metabolic benefits (site article). In preclinical models, Ang-(1-7) demonstrates cerebroprotective, anti-cancer, and reproductive system effects, with validated protocols for in vitro and in vivo use. Its high purity, water solubility, and storage stability enhance research reliability. Ang-(1-7) is distinct in the renin–angiotensin system (RAS) for its counter-regulatory, multi-system action, as detailed below.

Biological Rationale

Angiotensin (1-7) is a naturally occurring heptapeptide hormone (sequence: Asp-Arg-Val-Tyr-Ile-His-Pro) produced from angiotensin I or II by endo- or carboxypeptidases (Oliveira et al., 2025). It is a component of the non-classical renin–angiotensin system (RAS), which counterbalances the vasoconstrictive, pro-fibrotic, and pro-inflammatory actions of angiotensin II (Ang II) (site article). Unlike Ang II, which primarily acts via the AT1R receptor to induce hypertension, fibrosis, and inflammation, Ang-(1-7) signals predominantly through the Mas receptor, exerting vasodilatory, anti-fibrotic, and anti-inflammatory effects. This mechanistic opposition underlies the rationale for using Ang-(1-7) in cardiovascular, renal, and metabolic disease research (Angiotensin (1-7) product page).

Mechanism of Action of Angiotensin (1-7)

Ang-(1-7) binds with high affinity to the Mas receptor, a G protein-coupled receptor, initiating distinct intracellular cascades. Central pathways modulated include:

• PI3K/AKT signaling: Ang-(1-7) activates PI3K/AKT, promoting nitric oxide (NO) synthesis and endothelial function (Oliveira et al., 2025).
• ERK pathway regulation: It inhibits pathological ERK1/2 phosphorylation, reducing fibrotic and inflammatory gene expression (site article).
• Downstream effectors: Forkhead box O1 (FOXO1) and cyclo-oxygenase-2 (COX-2) are modulated, affecting apoptosis, oxidative stress, and inflammation.

Through these mechanisms, Ang-(1-7) reduces TGF-β-driven myofibroblast transition, enhances glucose uptake, stimulates lipolysis, and improves insulin sensitivity. In addition, it attenuates pro-inflammatory cytokine production and supports anti-fibrotic remodeling in multiple tissues (site article).

Evidence & Benchmarks

• Ang-(1-7) is generated from Ang I (1–10) or Ang II (1–8) via enzymatic cleavage by ACE2, neprilysin, or prolyl-endopeptidase (DOI:10.3390/ijms26136067).
• In cell-based assays, 100 nM Ang-(1-7) inhibits TGF-β-ERK-mediated myofibroblast transition in rat NRK-52E kidney cells; this effect is reversed by the Mas antagonist A779 (product documentation).
• In vivo, daily intraperitoneal Ang-(1-7) (0.01–0.06 mg/kg) ameliorates dextran sulfate sodium-induced colitis in BALB/c mice by reducing p38, ERK1/2, and Akt phosphorylation (product documentation).
• Ang-(1-7) increases glucose uptake and lipolysis, reducing insulin resistance and dyslipidemia, in metabolic disease models (site article).
• It confers cerebroprotection in ischemic stroke models and improves learning and memory in preclinical studies (DOI:10.3390/ijms26136067).
• Purity of Ang-(1-7) is typically >99.7% (HPLC, MS), with water solubility ≥48.5 mg/mL, and DMSO solubility ≥89.9 mg/mL (product documentation).

Applications, Limits & Misconceptions

Ang-(1-7) is a research tool for:

• Renal and cardiovascular disease models where anti-fibrotic and anti-inflammatory mechanisms are under investigation (site article; this article extends coverage to metabolic and neuroprotective contexts).
• Metabolic regulation, including studies on glucose uptake, lipolysis, and insulin resistance (site article; here, we clarify in vivo dosing and protocol details).
• Neuroprotection in models of ischemic stroke and cognitive decline (DOI:10.3390/ijms26136067).
• Reproductive system research, covering ovulation, spermatogenesis, and steroidogenesis.
• Anti-cancer investigations focusing on inhibition of cell proliferation and angiogenesis.

Common Pitfalls or Misconceptions

• Ang-(1-7) is not a direct antagonist of angiotensin II; its effects are mediated via the Mas receptor, not through AT1R/AT2R blockade.
• The peptide is ineffective in ethanol-based solutions due to insolubility; use only water or DMSO for preparation.
• Chronic, unbuffered solution storage at room temperature degrades activity; adhere to -20°C desiccated storage, and use solutions short-term only.
• It is not a replacement for AT1R antagonists in hypertensive models but rather a complementary tool for dissecting non-classical RAS pathways.
• No evidence supports direct efficacy in acute viral infection mitigation, despite RAS involvement in COVID-19 pathogenesis (DOI:10.3390/ijms26136067).

Workflow Integration & Parameters

For in vitro studies, Ang-(1-7) is typically applied at 100 nM in cell culture systems (e.g., NRK-52E rat kidney cells) to inhibit TGF-β-ERK pathway activity. The effect can be antagonized by A779, confirming Mas receptor-specific action. In vivo protocols employ daily intraperitoneal injections (0.01–0.06 mg/kg) in murine models, with endpoints including histological and signaling readouts (e.g., p38, ERK1/2, Akt phosphorylation). Peptide purity (>99.7%) and storage (-20°C, desiccated) are critical for reproducibility. Solutions should be freshly prepared in water or DMSO, never ethanol. For extended protocol guidance and comparative benchmarks, refer to the detailed workflow analyses in this internal article (this article clarifies dosing and storage optimizations beyond classical RAS ligands).

Conclusion & Outlook

Angiotensin (1-7) is a rigorously validated, multi-system tool for dissecting anti-fibrotic, anti-inflammatory, metabolic, and neuroprotective mechanisms. Its unique Mas receptor agonism and robust pathway modulation differentiate it from classical RAS agents, supporting advanced translational research. The documented purity, solubility, and protocol reliability of the A1041 kit provide confidence for reproducible results. Future studies are expected to further define its therapeutic and research utility across disease models and mechanistic contexts.